{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Smyth LM"],"funding":["NCI NIH HHS","National Breast Cancer Foundation","NIH"],"pagination":["198-213"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7007377"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(2)"],"pubmed_abstract":["<i>HER2</i> mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with <i>HER2</i>-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER<sup>+</sup> patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating <i>HER2</i> or <i>HER3</i> alterations were associated with poor treatment outcome. Similarly, acquisition of multiple <i>HER2</i>-activating events, as well as gatekeeper alteration"],"journal":["Cancer discovery"],"pubmed_title":["Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer."],"pmcid":["PMC7007377"],"funding_grant_id":["P30 CA016672","R01 CA234361","P30 CA008748","R01 CA190642","EC-17-001"],"pubmed_authors":["Scaltriti M","Baselga J","Samoila A","Sohn J","Zimel C","Saura C","Gonzalez-Farre X","Chandarlapaty S","Dujka M","Jhaveri K","Shapiro GI","Juric D","Piha-Paul SA","Arnedos M","Mau-Sorensen M","Smyth LM","Selcuklu SD","Meric-Bernstam F","Ulaner GA","Lalani AS","Bryce R","Arteaga CL","Spanggaard I","Gorelick AN","Xu F","Brufksy AM","Cervantes A","Won HH","Bidard FC","Schwartzberg LS","Hyman DM","Boni V","Mayer IA","Gavrila EI","Melcer M","Mann G","Moreno V","Lanman RB","Eli LD","Lu J","Cai Y","Taylor BS","Schram AM","Loi S","Nagy RJ","de la Fuente MI","Solit DB"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer.","description":"<i>HER2</i> mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with <i>HER2</i>-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER<sup>+</sup> patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating <i>HER2</i> or <i>HER3</i> alterations were associated with poor treatment outcome. Similarly, acquisition of multiple <i>HER2</i>-activating events, as well as gatekeeper alteration","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Feb","modification":"2025-04-19T01:02:18.931Z","creation":"2020-10-29T12:35:50Z"},"accession":"S-EPMC7007377","cross_references":{"pubmed":["31806627"],"doi":["10.1158/2159-8290.CD-19-0966","10.1158/2159-8290.cd-19-0966"]}}